Union Chimique Belge (UCB) has announced the release of new positive data regarding Bimzelx (bimekizumab) in moderate to ...

ASH 2025 showed up with a clenched fist and never loosened it. Under the rallying call of ‘Fight 4 Hematology’, the meeting ...

While obstructive sleep apnea (OSA) affects approximately 32% of US adults—nearly 80 million people—it remains an "epidemic hiding in plain sight". Perhaps most staggering is that 90% of women with ...

Gastric cancer is the fifth highest cause of cancer deaths worldwide, with almost a million people diagnosed annually ...

McNamara’s Fallacy is the error of making decisions based solely on easily quantifiable data, while ignoring ...

With GENEROUS, GUARD, and GLOBE all released since December, 185 pages of policy will materially impact U.S. drug pricing — ...

Sanofi has announced that its Rezurock (belumosudil) has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for the ...

Skyhawk Therapeutics has announced positive interim results from its phase 1 trial of SKY-0515, an investigational treatment ...

Johnson & Johnson has announced that its Darzalex Faspro-based regimen (daratumumab and hyaluronidase, in combination with ...

Alzheimer’s disease (AD) continues to be one of the most challenging conditions facing patients, families and healthcare ...

Biogen’s litifilimab has received Breakthrough Therapy Designation from the US FDA to treat cutaneous lupus erythematosus ...

Boehringer Ingelheim and Simcere have announced a new license and collaboration agreement for the development of SIM0709, a ...